Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: A controlled, randomized, open-label phase II trial

Oncologist

Volumn 12, Issue 6, 2007, Pages 727-737

  Charu, Veena ^a   Belani, Chandra P ^b   Gill, Ahmad N ^c   Bhatt, Mukesh ^d   Tomita, Dianne ^e   Rossi, Greg ^e   Ben Jacob, Ali ^f  

^a Pacific Cancer Medical Center   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c Carolina Cancer Center   (United States)

^d Medina General Hospital   (United States)

^e AMGEN INC   (United States)

^f Cache Valley Cancer Treatment and Research Center   (United States)

Author keywords

Anemia of cancer; Darbepoetin alfa; Randomized controlled trial

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PULMONARY EMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34447115042     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-6-727     Document Type: Article

References (32)

1. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
2. Moliterno AR, Spivak JL. Anemia of cancer. Hematol Oncol Clin North Am 1996;10:345-363.
3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
4. Miller CB, Jones RJ, Piantadosi S et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
5. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-46.
6. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
7. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. Semin Hematol 1997;34(suppl 2):4-12.
8. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37(suppl 6):14-17.
9. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
10. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
11. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
12. Glaspy JA, Jadeja JS, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
13. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
14. Kotasek D, Steger G, FaughtWet al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034.
15. Littlewood TJ, Bajetta E, Nortier JW et al.; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
16. Schwartzberg LS, Yee LK, Senecal FM et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. The Oncologist 2004;9:696-707.
17. Vadhan-Raj S, Mirtsching B, Charu V et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. J Support Oncol 2003;1:131-138.
18. Vansteenkiste J, Pirker R, Massuti B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
19. Abels R, Larholt K, Krantz K et al. Recombinant human erythropoietin (r-HuEPO) for the treatment of anemia of cancer. In: Murphy M, ed. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Proceedings of the Beijing Symposium. Dayton, OH: AlphaMed Press, 1991:121-141.
20. Quirt I, Robeson C, Lau CY et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001;19:4126-4134.
21. Smith RE Jr, Tchekmedyian NS, Chan D et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-1858.
22. Lyman GH, Kuderer NM. Cost effectiveness of myeloid growth factors in cancer chemotherapy. Curr Hematol Rep 2003;2:471-479.
23. Cella D, Eton DT, Lai JS et al. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24:547-561.
24. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004;116(suppl 7A):11S-26S.
25. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
26. Ludwig H, Fritz E, Leitgeb C et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994;84:1056-1063.
27. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
28. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
29. Amgen Inc., Aranesp® (darbepoetin alfa) package insert. Thousand Oaks, CA; 2006.
30. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-2216.
31. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
32. Rodgers GM. Clinical practice guidelines in oncology. Cancer- and treatment-related anemia. 2006. http://www.nccn.org/professionals/physician_gls/ f_guidelines.asp. Accessed March 2006.